Jaykumar Thumar, MBBS, MD
DownloadHi-Res Photo
About
Titles
Adjunct Assistant Professor
Biography
Dr Thumar completed his residency (Internal Medicine) from Civil Hospital, Ahmedabad, India. During his medical training at Gujarat Cancer Research Institute he developed major interest in medical oncology and basic science research. He served as post doctoral research fellow at Center for Vascular Biology, University of Connecticut. He completed his additional internship and residency training in internal medicine at University of Connecticut, Farmington, CT. He served as Chief Medical Resident at John Dempsey Hospital, Farmington, CT. He then served as a Fellow in Hematology and Oncology at Yale Cancer Center, New Haven, CT.
Appointments
Medical Oncology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology
- Subset Medical Oncology Faculty
- Yale Cancer Center
Education & Training
- MD
- Yale University, Medical Hematology Oncology (2012)
- Chief Medical Resident
- University of Connecticut (2009)
- MD
- University of Connecticut, Internal Medicine (2008)
- MBBS
- B.J. Medical College (2000)
Research
Clinical Trials
Current Trials
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
HIC ID2000026850RoleSub InvestigatorPrimary Completion Date12/31/2024Recruiting ParticipantsRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
HIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
HIC ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting ParticipantsGBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
HIC ID2000026339RoleSub InvestigatorPrimary Completion Date06/30/2026Recruiting Participants